P24941 (CDK2_HUMAN) Homo sapiens (Human)
Cyclin-dependent kinase 2 UniProtKBInterProSTRINGInteractive Modelling
It is possible new templates exist for this target since these models were created.
Available Structures
462 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Thr 160 phosphorylated CDK2 H84S, Q85M, K89D - human cyclin A3 complex with ATP |
Heteromer P20248; | 98.98 | 1×ATP; 2×MG; 2×SGM; | |||
| CDK2/CyclinA in complex with AZD5438 |
Heteromer P30274; | 99.66 | 1×FB8; | |||
| CDK2/Cyclin A covalent complex with 6-(cyclohexylmethoxy)-N-(4-(vinylsulfonyl)phenyl)-9H-purin-2-am… |
Heteromer P20248; | 100 | 1×55S; | |||
| Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor meriolin 3 |
Heteromer P30274; | 100.0 | 1×MFR; 1×MG; 2×SGM; | |||
| Thr 160 phosphorylated CDK2 K89D, Q131E - human cyclin A3 complex with the inhibitor RO3306 |
Heteromer P20248; | 99.32 | 1×1RO; 1×DMS; 1×SGM; | |||
| Structure of CDK2/cyclin A in complex with CAN508 |
Heteromer P30274; | 100.0 | 1×F18; | |||
| Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor |
Heteromer P30274; | 100 | 1×T6Q; 2×SGM; 1×SO4; | |||
| Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor variolin B |
Heteromer P30274; | 100.0 | 1×VAR; 1×MG; 2×SGM; | |||
| CDk2/cyclinA in complex with DRB |
Heteromer P30274; | 100.0 | 1×RFZ; 3×FMT; 1×SGM; | |||
| Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. |
Heteromer P20248; | 100.0 | 1×2WC; 1×MG; | |||
| Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor |
Heteromer P20248; | 100 | 1×T3C; 1×SO4; 2×SGM; | |||
| Structure of CDK2/Cyclin A with PNU-292137 |
Heteromer P20248; | 100 | 1×SO4; 1×292; | |||
| CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX |
Heteromer P20248; | 100 | 1×ATP; | |||
| Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor meriolin 5 |
Heteromer P30274; | 100.0 | 1×MHR; 1×MG; | |||
| STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 |
Heteromer P20248; | 100 | 1×529; 1×SO4; | |||
| Thr 160 phosphorylated CDK2 H84S, Q85M, Q131E - human cyclin A3 complex with the inhibitor RO3306 |
Heteromer P20248; | 98.99 | 1×1RO; 1×MG; | |||
| Structure of phopsho-CDK2-cyclin A in complex with an ATP-competitive inhibitor |
Heteromer P20248; | 100.0 | 1×6ZK; 1×SGM; 1×MG; | |||
| CDK-2-Cyclin complex with indazole inhibitor 9 bound at its active site |
Heteromer P20248; | 100 | 4×GOL; 4×EZV; 2×SO4; | |||
| Structure of Thr 160 phosphorylated CDK2/cyclin A in complex with the inhibitor NU6271 |
Heteromer P30274; | 100 | 1×NU5; | |||
| STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125 |
Heteromer P20248; | 100 | 1×P48; | |||
| CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2 |
Heteromer P89883; | 100.0 | 1×CL; | |||
| Optimisation of 6,6-Dimethyl Pyrrolo 3,4-c pyrazoles: Identification of PHA-793887, a Potent CDK In… |
Heteromer P20248; | 100 | 1×SO4; 1×889; | |||
| Crystal structure of the Cyclin A-CDK2-ORC1 complex |
Heteromer P20248; Q13415; | 100 | 4×PO4; | |||
| PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A |
Heteromer P20248; | 100 | 2×MN; 2×ATP; | |||
| STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 |
Heteromer P20248; | 100 | 1×SBC; 1×SO4; | |||
| Structure of CDK2-CYCLIN A with a Pyrazolo(4,3-h) quinazoline-3- carboxamide inhibitor |
Heteromer P20248; | 100 | 1×WXV; 1×SO4; | |||
| Crystal structure apo CDK2/cyclin A |
Heteromer P20248; | 100 | ||||
| CDK2/CyclinA in complex with CGP74514A |
Heteromer P30274; | 100.0 | 1×23D; | |||
| Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor CR8 |
Heteromer P30274; | 100 | 1×RC8; | |||
| Crystal Structure of the CDK2/Cyclin A complex with oxindole inhibitor |
Heteromer P20248; | 100 | 1×60K; 2×DTT; | |||
| THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR |
Heteromer P20248; | 100 | 1×107; | |||
| STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1-METHYL-4,5-DIHYDRO- 1H-PYRAZOLO[4,3-H] QUINAZ… |
Heteromer P20248; | 100.0 | 1×P49; | |||
| Cdk2/CyclinA complexed with a imidazo triazin-2-amine |
Heteromer P20248; | 100.0 | 1×T2A; | |||
| CDK2/CyclinA complexed with a pyrazolopyridazine inhibitor |
Heteromer P20248; | 100.0 | 1×5BP; | |||
| Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. |
Heteromer P20248; | 100 | 1×G6T; | |||
| Cryo-EM structure of CDK2-cyclin A in complex with CDC25A |
Heteromer P30274; P30304; | 100 | ||||
| Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor roscovitine |
Heteromer P30274; | 100.0 | 1×RRC; 1×SGM; | |||
| CDK2-CyclinE1 in complex with allosteric inhibitor I-198. |
Heteromer P24864; | 100 | 1×A1AC4; | |||
| CDK2-CyclinE1 in complex with allosteric inhibitor I-125A. |
Heteromer P24864; | 100.0 | 1×A1AC5; | |||
| Thr 160 phosphorylated CDK2 Q131E - human cyclin A3 complex with the inhibitor RO3306 |
Heteromer P20248; | 99.66 | 1×1RO; 1×SGM; | |||
| Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-pu… |
Heteromer P20248; | 100.0 | 1×N76; 1×SGM; 1×MG; | |||
| Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor |
Heteromer P20248; | 100 | 1×T3E; 1×SGM; | |||
| Structure of CDK2 in complex with FP19711, a Helicon Polypeptide |
Heteromer | 100.0 | 1×NH2; 1×WHL; | |||
| Thr 160 phosphorylated CDK2 H84S, Q85M, Q131E - human cyclin A3 complex with ATP |
Heteromer P20248; | 98.98 | 1×ATP; 1×MG; | |||
| Thr 160 phosphorylated CDK2 Q131E - human cyclin A3 complex with ATP |
Heteromer P20248; | 99.66 | 2×MG; 1×ATP; 1×SGM; | |||
| The structural basis of CDK2 activation by cyclin E |
Heteromer P24864; | 100 | ||||
| Thr 160 phosphorylated CDK2 WT - human cyclin A3 complex with ATP |
Heteromer P20248; | 100.0 | 1×ATP; 2×MG; 1×SGM; | |||
| Crystal structure of CDK2/cyclin E in complex with PF-06873600 |
Heteromer P24864; | 100 | 1×WG1; | |||
| CDK2/CyclinA in complex with an 11-residue recruitment peptide from p27 |
Heteromer P20248; P46527; | 100 | ||||
| Thr 160 phosphorylated CDK2 WT - human cyclin A3 complex with the inhibitor NU6102 |
Heteromer P20248; | 100.0 | 1×4SP; | |||
| CDK2/CyclinA in complex with an 11-residue recruitment peptide from p53 |
Heteromer P04637; P20248; | 100 | ||||
| Mechanism of CDK inhibition by active site phosphorylation: CDK2 Y15p T160p in complex with cyclin … |
Heteromer P20248; | 100 | 1×ATP; | |||
| STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V-H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGU… |
Heteromer P20248; | 98.99 | 1×4SP; 1×SGM; | |||
| Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor |
Heteromer P20248; | 100 | 1×C94; | |||
| Thr 160 phosphorylated CDK2 H84S, Q85M, K89D - human cyclin A3 complex with the inhibitor RO3306 |
Heteromer P20248; | 98.98 | 1×1RO; 1×SGM; 1×MG; | |||
| Complex structure of CDK2/Cyclin E1 and a potent, selective macrocyclic inhibitor |
Heteromer P24864; | 100 | 1×WZU; | |||
| Thr 160 phosphorylated CDK2 WT - human cyclin A3 complex with the inhibitor RO3306 |
Heteromer P20248; | 100.0 | 1×1RO; | |||
| Thr 160 phosphorylated CDK2 H84S, Q85M, K89D - human cyclin A3 complex with the inhibitor NU6102 |
Heteromer P20248; | 98.98 | 1×4SP; 1×SGM; | |||
| STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-N… |
Heteromer P20248; | 100.0 | 1×ST8; 1×SGM; | |||
| STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 |
Heteromer P20248; | 100 | 1×SO4; 1×514; | |||
| Structure of Thr 160 phosphorylated CDK2/cyclin A in complex with the inhibitor N-&-N1 |
Heteromer P30274; | 100.0 | 1×NNN; 1×SGM; | |||
| Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design |
Heteromer P20248; | 100 | 1×X1N; | |||
| The X-ray co-crystal structure of human CDK2/CyclinE and Dinaciclib. |
Heteromer P24864; | 100 | 1×1QK; 1×GOL; | |||
| Cdk2/Cyclin A complexed with a thiophene carboxamide inhibitor |
Heteromer P20248; | 100.0 | 1×BLZ; | |||
| Complex structure of CDK2/Cyclin E1 and a potent, selective small molecule inhibitor |
Heteromer P24864; | 100 | 1×WZZ; | |||
| CDK2/CyclinA complexed with a pyrazolopyridazine inhibitor |
Heteromer P20248; | 100.0 | 1×PO5; | |||
| Crystal structure of SUN1-Speedy A-CDK2 |
Heteromer O94901; Q5MJ70; | 100 | 2×GOL; 2×ZN; | |||
| The crystal structure of CDK2 cyclin A in complex with a substrate peptide derived from CDC modifie… |
Heteromer P20248; Q99741; | 100 | 1×ATP; 1×SO4; 2×GOL; | |||
| Structure of a pCDK2/CyclinA transition-state mimic |
Heteromer P51943; | 100 | 1×ADP; 2×MG; 1×MGF; 1×CL; 1×DTU; | |||
| Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6086 |
Heteromer P20248; | 100 | 1×6CP; | |||
| Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6102 |
Heteromer P20248; | 100 | 1×4SP; | |||
| CDK2/CyclinA in complex with SU9516 |
Heteromer P30274; | 100.0 | 1×SU9; | |||
| STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR |
Heteromer P20248; | 99.63 | 1×4SP; 1×SGM; 1×MG; | |||
| Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. |
Heteromer P20248; | 100.0 | 1×75X; 2×MG; | |||
| Structure of pCDK2/CyclinA bound to ADP and 2 Magnesium ions |
Heteromer P51943; | 100 | 1×ADP; 2×MG; 5×GOL; 1×CL; | |||
| REPLACE: A strategy for Iterative Design of Cyclin Binding Groove Inhibitors |
Heteromer P20248; | 100 | 1×MTZ; 1×GVC; | |||
| Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design |
Heteromer P20248; | 100 | 1×CK2; | |||
| Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU2058 |
Heteromer P20248; | 100 | 1×CMG; | |||
| Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design |
Heteromer P20248; | 100 | 1×CK8; | |||
| Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-pu… |
Heteromer P20248; | 100.0 | 1×N20; 1×SGM; 1×MG; | |||
| Structure of PCDK2/CYCLINA bound to ADP and 1 MAGNESIUM ION |
Heteromer P51943; | 100 | 1×ADP; 1×MG; 3×GOL; | |||
| Structure of a pCDK2/CyclinA transition-state mimic |
Heteromer P51943; | 100 | 1×ADP; 2×MG; 1×MGF; 1×CL; 10×GOL; | |||
| PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX |
Heteromer P20248; | 100 | 2×ATP; 2×MG; | |||
| The structure of phospho-CDK2/cyclin A in complex with the inhibitor 4,5,6,7-tetrabromobenzotriazol… |
Heteromer P20248; | 100 | 1×TBS; | |||
| THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A |
Heteromer P20248; | 100 | 1×UCN; | |||
| Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design |
Heteromer P20248; | 100 | 1×CK7; | |||
| Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor |
Heteromer P20248; | 100 | 1×C95; | |||
| Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-pu… |
Heteromer P20248; | 100.0 | 1×N41; 1×SGM; 1×MG; | |||
| Cyclin A binding groove inhibitor H-Arg-Arg-Leu-Ile-Phe-NH2 |
Heteromer P20248; | 100 | ||||
| Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. |
Heteromer P20248; | 100 | 1×SQ9; | |||
| Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor |
Heteromer P20248; | 100.0 | 1×T7Z; 1×SGM; | |||
| Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6094 |
Heteromer P20248; | 100 | 1×2A6; | |||
| Thr 160 phosphorylated CDK2 - Human cyclin A3 complex with the inhibitor indirubin-5-sulphonate bou… |
Heteromer P20248; | 100 | 1×INR; | |||
| Cyclin A binding groove inhibitor Ac-Arg-Arg-Leu-Asn-(m-Cl-Phe)-NH2 |
Heteromer P20248; | 100 | ||||
| CDK2/CyclinA in complex with Flavopiridol |
Heteromer P30274; | 100.0 | 1×F9Z; | |||
| Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design |
Heteromer P20248; | 100 | ||||
| REPLACE: A strategy for Iterative Design of Cyclin Binding Groove Inhibitors |
Heteromer P20248; | 100 | 1×C35; | |||
| Cyclin A binding groove inhibitor Ace-Arg-Lys-Leu-Phe-Gly |
Heteromer P20248; | 100 | ||||
| Cyclin A binding groove inhibitor H-Arg-Arg-Leu-Asn-(p-F-Phe)-NH2 |
Heteromer P20248; | 100 | ||||
| Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment sit… |
Heteromer P20248; | 100 | 1×MG; | |||
| Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor |
Heteromer P20248; | 100 | 1×DT5; | |||
| Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor |
Heteromer P20248; | 100 | 1×C75; | |||
| Crystal structure of human Cdk2-Spy1 complex |
Heteromer Q5MJ70; | 100 | ||||
| Crystal structure of phospho-CDK2 Cyclin A in complex with a peptide containing both the substrate … |
Heteromer P20248; Q99741; | 100 | 1×ATP; 1×MG; | |||
| pCDK2/cyclin A in complex with MgADP, nitrate and peptide substrate |
Heteromer P20248; | 100 | 1×ATP; 1×MG; 1×NO3; 1×GOL; | |||
| Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor |
Heteromer P20248; | 100 | 1×C85; | |||
| CDK2/CyclinA in complex with an 11-residue recruitment peptide from p107 |
Heteromer P20248; P28749; | 100 | ||||
| Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment sit… |
Heteromer P20248; | 100 | ||||
| Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. |
Heteromer P20248; | 100 | 1×4QE; | |||
| Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design |
Heteromer P20248; | 100 | 1×MTW; | |||
| Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design |
Heteromer P20248; | 100 | ||||
| Cyclin A binding groove inhibitor H-Cit-Cit-Leu-Ile-(p-F-Phe)-NH2 |
Heteromer P20248; | 100 | ||||
| Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design |
Heteromer P20248; | 100 | 1×CK4; | |||
| CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2 |
Heteromer Q16667; | 100 | 1×MG; 1×ATP; | |||
| Crystal Structure Analysis of human CDK2 and CCNA2 complex |
Heteromer P20248; | 100 | 1×ZGY; | |||
| STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR |
Heteromer P20248; | 99.66 | 1×QQ2; 1×SGM; 1×MG; | |||
| CDK2/Cyclin A in complex with compound 73 |
Heteromer P20248; | 100 | 1×72L; | |||
| Crystal structure of Cyclin-dependent kinase 2/cyclin A in complex with 3,5,7-Substituted pyrazolo[… |
Heteromer P20248; | 100.0 | 1×D5P; 1×GOL; 4×EDO; 2×PEG; 1×SGM; | |||
| CDK2/cyclin A2 in complex with an imidazo[1,2-c]pyrimidin-5-one inhibitor |
Heteromer P20248; | 100 | 1×R7B; 6×EDO; 1×NA; | |||
| Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor |
Heteromer P20248; | 100 | 1×T9N; 1×SO4; | |||
| Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. |
Heteromer P20248; | 100 | 1×JYM; 1×DTT; | |||
| Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor |
Heteromer P30274; | 100.0 | 1×TJF; | |||
| CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1 |
Heteromer P61024; | 100.0 | ||||
| CDK2/cyclin A2 in complex with pyrazolo[4,3-d]pyrimidine inhibitor LGR6768 |
Heteromer P20248; | 100.0 | 1×P2V; 2×GOL; 1×EDO; | |||
| Crystal structure of human Cdk2-Spy1 complex |
Heteromer Q5MJ70; | 100.0 | ||||
| CDK2/CyclinA in complex with a 9 residue recruitment peptide from E2F |
Heteromer P20248; Q01094; | 100 | ||||
| CDK2/Cyclin A in complex with an 11-residue recruitment peptide from retinoblastoma-associated prot… |
Heteromer P06400; P20248; | 100 | ||||
| CDK2/cyclin A2 in complex with 3H-pyrazolo[4,3-f]quinoline-based derivative HSD1368 |
Heteromer P20248; | 100.0 | 1×T1T; 1×NO3; 1×SO4; | |||
| CDK2/cyclin A2 in complex with pyrazolo[4,3-d]pyrimidine inhibitor LGR4455 |
Heteromer P20248; | 100.0 | 1×FCQ; 3×EDO; 1×CL; 1×BR; 1×PG4; 1×SGM; 1×PGE; | |||
| CDK2/cyclin A2 in complex with open-ring 5-nitrosopyrimidine inhibitor LC436 |
Heteromer P20248; | 100 | 1×K4W; 2×NA; 2×GOL; | |||
| Crystal structure of phospho-CDK2 in complex with Cyclin B |
Heteromer P14635; | 100 | ||||
| P27(KIP1)/CYCLIN A/CDK2 COMPLEX |
Heteromer P20248; P46527; | 100 | 1×SO4; | |||
| Ubiquitin ligation to F-box protein substrates by SCF-RBR E3-E3 super-assembly: CUL1-RBX1-SKP1-SKP2… |
Heteromer P20248; P46527; P61024; P63208; Q13309; Q13616; | 100.0 | ||||
| Ubiquitin ligation to F-box protein substrates by SCF-RBR E3-E3 super-assembly: NEDD8-CUL1-RBX1-SKP… |
Heteromer P0CG48; P20248; P46527; P61024; P62877; P63208; P68036; Q13309; Q13616; Q15843; Q9Y4X5; | 100.0 | 9×ZN; 1×SY8; | |||
| Cryo-EM structure of CDK2-CyclinA in complex with p27 from the SCFSKP2 E3 ligase Complex |
Heteromer P20248; P46527; | 100 | ||||
| Cdk2/cyclin A/p27-KID-deltaC |
Heteromer P20248; P46527; | 100.0 | 1×SO4; | |||
| Cryo-EM structure of SKP1-SKP2-CKS1-CDK2-CyclinA-p27KIP1 Complex |
Heteromer P20248; P46527; P61024; P63208; Q13309; | 99.64 | ||||
| Crystal structure of human Cdk2-Spy1-P27 ternary complex |
Heteromer P46527; Q5MJ70; | 100.0 | ||||
| Structure of CDK2/cyclin A M246Q, S247EN |
Heteromer P20248; | 100.0 | ||||
| CAND1-CUL1-RBX1-SKP1-SKP2-CKS1-CDK2 |
Heteromer P61024; P62877; P63208; Q13309; Q13616; Q86VP6; | 100.0 | 3×ZN; | |||
| Partially dissociated CAND1-CUL1-RBX1-SKP1-SKP2-CKS1-CDK2 |
Heteromer P61024; P62877; P63208; Q13309; Q13616; Q86VP6; | 100.0 | ||||
| CDK2 in complex with FragLite37 | monomer | 99.64 | 1×HJK; | |||
| CDK2 in complex with FragLite6 | monomer | 100.0 | 1×DMS; 1×HGQ; | |||
| CDK2 in complex with FragLite36 | monomer | 100.0 | 1×HGH; 1×DMS; | |||
| CDK2 in complex with FragLite34 | monomer | 100.0 | 2×DMS; 1×HHB; | |||
| CDK2 in complex with FragLite33 | monomer | 100.0 | 2×DMS; 1×HH5; | |||
| CDK2 in complex with FragLite38 | monomer | 100.0 | 2×HHW; 1×EDO; | |||
| CDK2 in complex with FragLite2 | monomer | 100.0 | 2×PYZ; | |||
| CDK2 in complex with FragLite35 | monomer | 99.65 | 1×DMS; 1×HGK; | |||
| CDK2 in complex with FragLite13 | monomer | 100.0 | 1×HHN; | |||
| CDK2 in complex with FragLite14 | monomer | 100.0 | 1×HGW; | |||
| CDK2 in complex with FragLite2 | monomer | 100.0 | 1×HEW; | |||
| CDK2 in complex with FragLite32 | monomer | 100.0 | 1×26D; | |||
| Crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitor | monomer | 100.0 | 1×CK2; | |||
| Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor | monomer | 100.0 | 1×SCF; | |||
| HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-Amino-6-(3'-methyl-2'-oxo)butoxypuri… | monomer | 100.0 | 1×MBP; | |||
| CCT068127 in complex with CDK2 | monomer | 100.0 | 1×8QT; | |||
| CDK2 in complex with CGP74514A | monomer | 100.0 | 1×FC8; | |||
| Cyclin-free CDK2 in complex with Cpd17 | monomer | 100.0 | 1×WQ6; | |||
| Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor | monomer | 100.0 | 1×5SC; | |||
| CDK2 in complex 9K-DOS | monomer | 100.0 | 1×JLC; | |||
| CDK2 in complex with inhibitor RC-3-89 | monomer | 100 | 4×EDO; 1×X64; | |||
| Crystal structure of the cdk2 in complex with oxindole inhibitor | monomer | 100.0 | 2×60K; 1×GOL; | |||
| Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor | monomer | 100.0 | 1×6SC; | |||
| Crystal structure of CDK2 in complex with TW8672 | monomer | 100 | 1×EDO; 1×7TW; | |||
| Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor | monomer | 100.0 | 1×SCE; | |||
| Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor | monomer | 100.0 | 1×SC8; | |||
| CDK2 in complex with AZD5438 | monomer | 100.0 | 1×FB8; 2×EDO; | |||
| Crystal structure of the cdk2 in complex with aminopyrazole inhibitor | monomer | 100.0 | 1×4CK; | |||
| A crystal form of a human CDK2-CDK7 chimera | monomer | 97.45 | 1×I74; | |||
| Crystal structure of the cdk2 in complex with aminopyrazole inhibitor | monomer | 100.0 | 1×10K; | |||
| Crystal structure of human CDK2 (unphosphorylated) in complex with PKF049-365 | monomer | 100.0 | 1×89E; | |||
| Crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitor | monomer | 100.0 | 1×20K; 1×ACT; | |||
| Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor | monomer | 100.0 | 1×SC9; | |||
| Crystal structure of CDK2 liganded with compound EF4195 | monomer | 100.0 | 4×EDO; 2×8KQ; | |||
| Crystal Structure of the Cdk2 in Complex with Aminopyrazole Inhibitor | monomer | 100.0 | 1×09K; | |||
| Crystal structure of the cdk2 in complex with oxindole inhibitor | monomer | 100.0 | 1×LS5; 1×NA; | |||
| CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-b]PYRIDAZINE | monomer | 100.0 | 1×I1P; | |||
| Crystal structure of the cdk2 in complex with aminopyrazole inhibitor | monomer | 100.0 | 1×03K; | |||
| CDK2 in complex with inhibitor KVR-2-80 | monomer | 100.0 | 1×EDO; 1×18Z; | |||
| CDK2 in complex with a disubstituted 4, 6-bis anilino pyrimidine CDK4 inhibitor | monomer | 100.0 | 1×FAP; 1×FCP; | |||
| Crystal Structure of CDK2 in complex with compound 22 | monomer | 100.0 | 1×6QB; | |||
| Crystal structure of the cdk2 in complex with aminopyrazole inhibitor | monomer | 100.0 | 1×11K; 1×ACT; | |||
| CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL]SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZIN… | monomer | 100.0 | 2×GOL; 1×7YG; | |||
| Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor | monomer | 100.0 | 1×SCZ; | |||
| CDK2 with compound 14 inhibitor with carboxylate | monomer | 100.0 | 1×YOS; | |||
| Cdk2(F80C) with Covalent Adduct TK22 at F80C | monomer | 99.31 | 1×OY2; | |||
| Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor | monomer | 100.0 | 1×SCJ; | |||
| Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor | monomer | 100.0 | 1×SCW; | |||
| Crystal structure of a CDK inhibitor bound to CDK2 | monomer | 100.0 | 1×6AE; | |||
| Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor | monomer | 100.0 | 1×3SC; | |||
| Cdk2(F80C) with Covalent Adduct TK37 at F80C | monomer | 99.29 | 1×OWN; | |||
| Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519… | monomer | 100.0 | 1×LZD; | |||
| CDK2 in complex with Dinaciclib | monomer | 100 | 1×EDO; 1×1QK; | |||
| Cdk2(F80C) | monomer | 99.33 | ||||
| CDK2 ternary complex with JWS648 and ANS | monomer | 100 | 2×2AN; 1×JWS; | |||
| Crystal structure of the cdk2 in complex with oxindole inhibitor | monomer | 100.0 | 1×61K; 1×GOL; | |||
| Crystal structure of CDK2 processed with the CrystalDirect automated mounting and cryo-cooling tech… | monomer | 100.0 | ||||
| Crystal structure of CDK2 in complex with 6-methoxy-7H-purine processed with the CrystalDirect auto… | monomer | 100.0 | 1×SZL; | |||
| CDK2 in complex with inhibitor L2 | monomer | 100.0 | 1×EDO; 1×X11; 1×PO4; | |||
| Crystal Structure of the CDK2 in complex with thiazolylpyrimidine inhibitor | monomer | 100.0 | 1×18K; 1×ACT; | |||
| Crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitor | monomer | 100.0 | 1×16K; | |||
| Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor | monomer | 100.0 | 1×SCQ; | |||
| Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor | monomer | 100.0 | 1×SCX; | |||
| CDK2 in complex with inhibitor KVR-1-164 | monomer | 100.0 | 1×EDO; 1×X87; | |||
| CDK2 in complex with inhibitor KVR-1-160 | monomer | 100.0 | 1×EDO; 1×X85; | |||
| CDK2 in complex with FragLite16 | monomer | 100.0 | 1×HH8; | |||
| CDK2 in complex with inhibitor KVR-1-162 | monomer | 100.0 | 1×EDO; 1×X86; | |||
| CDK2 in complex with inhibitor RC-2-49 | monomer | 100.0 | 1×25Z; | |||
| Crystal structure of the cdk2 in complex with oxindole inhibitor | monomer | 100.0 | 1×42K; 1×GOL; | |||
| CDK2 in complex with inhibitor RC-3-89 | monomer | 100.0 | 1×EDO; 1×X64; | |||
| CDK2 in complex with inhibitor KVR-1-156 | monomer | 100.0 | 1×EDO; 1×24Z; | |||
| CDK2 in complex with inhibitor KVR-1-154 | monomer | 100.0 | 1×EDO; 1×22Z; | |||
| CDK2 in complex with inhibitor RC-2-39 | monomer | 100.0 | 1×56Z; | |||
| CDK2 in complex with inhibitor JWS-6-76 | monomer | 100.0 | 2×EDO; 1×X67; | |||
| Crystal structure of CDK2 IN complex with Inhibitor CVT-313 | monomer | 100.0 | 1×AJR; | |||
| CDK2 in complex with inhibitor KVR-1-190 | monomer | 100.0 | 1×EDO; 1×X63; | |||
| CDK2 in complex with inhibitor KVR-1-84 | monomer | 100.0 | 1×EDO; 1×X65; | |||
| CDK2 in complex with inhibitor L1 | monomer | 100.0 | 1×EDO; 1×X07; | |||
| CDK2 in complex with inhibitor RC-2-33 | monomer | 100.0 | 1×20Z; | |||
| CDK2 in complex with inhibitor KVR-1-126 | monomer | 100.0 | 1×EDO; 1×X72; | |||
| CDK2 in complex with inhibitor NSK-MC2-55 | monomer | 100.0 | 2×EDO; 1×X14; | |||
| CDK2 in complex with inhibitor KVR-1-142 | monomer | 100.0 | 1×EDO; 1×X6A; | |||
| CDK2 in complex with inhibitor KVR-1-158 | monomer | 100.0 | 1×EDO; 1×X84; | |||
| CDK2 in complex with inhibitor RC-2-34 | monomer | 100.0 | 1×04Z; | |||
| CDK2 in complex with inhibitor RC-2-21 | monomer | 100.0 | 1×Z68; | |||
| CDK2 in complex with inhibitor SU9516 | monomer | 100.0 | 1×EDO; 1×PO4; 1×SU9; | |||
| CDK2 in complex with inhibitor KVR-1-75 | monomer | 100.0 | 1×EDO; 1×X96; | |||
| CDK2 in complex with inhibitor KVR-2-92 | monomer | 100.0 | 1×EDO; 1×Z14; | |||
| CDK2 in complex with inhibitor KVR-1-140 | monomer | 100.0 | 1×EDO; 1×XA0; | |||
| CDK2 in complex with inhibitor RC-2-22 | monomer | 100.0 | 1×O1Z; | |||
| CDK2 in complex with inhibitor RC-2-32 | monomer | 100.0 | 1×03Z; | |||
| Human CDK2 in complex with isopentenyladenine | monomer | 100 | 1×ZIP; | |||
| CDK2 in complex with two molecules of 8-anilino-1-naphthalene sulfonate | monomer | 100 | 5×EDO; 2×2AN; | |||
| Crystal structure of cdk2 with an aminoimidazo pyridine inhibitor | monomer | 100 | 1×628; | |||
| Crystal structure of the cdk2 in complex with oxindole inhibitor | monomer | 100.0 | 1×62K; 1×GOL; | |||
| Novel CDK-5 inhibitors - crystal structure of inhibitor EFP with CDK-2 | monomer | 100.0 | 1×EFP; | |||
| CDK2 in complex with inhibitor RC-1-137 | monomer | 100.0 | 1×EDO; 1×X35; | |||
| 4-Arylazo-3,5-diamino-1H-pyrazole CDK Inhibitors: SAR Study, Crystal Structure in Complex with CDK2… | monomer | 100.0 | 1×F18; | |||
| CDK2 in complex with a disubstituted 2, 4-bis anilino pyrimidine CDK4 inhibitor | monomer | 100.0 | 1×BYP; 1×BWP; 1×GOL; | |||
| Crystal Structure of the CDK2 in complex with thiazolylpyrimidine inhibitor | monomer | 100.0 | 1×19K; | |||
| CDK2 in complex with inhibitor RC-2-88 | monomer | 100.0 | 1×EDO; 1×26Z; | |||
| Novel CDK-5 inhibitors - crystal structure of inhibitor EFQ with CDK-2 | monomer | 100.0 | 1×EFQ; | |||
| CDK2 in complex with inhibitor L4-14 | monomer | 100.0 | 1×Z60; | |||
| CDK2 in complex with inhibitor JWS648 | monomer | 100.0 | 1×JWS; 1×PO4; | |||
| CDK2 in complex with inhibitor RC-2-71 | monomer | 100.0 | 1×EDO; 1×08Z; | |||
| CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(1,1-DIMETHYLETHYL)… | monomer | 100.0 | 1×56H; | |||
| CDK2 in complex with inhibitor L3-3 | monomer | 100.0 | 1×PO4; 1×Z19; | |||
| CDK2 in complex with inhibitor NSK-MC1-6 | monomer | 100.0 | 1×Z46; | |||
| CDK2 in complex with inhibitor KVR-1-134 | monomer | 100.0 | 1×EDO; 1×X76; | |||
| HUMAN CYCLIN-DEPENDENT KINASE 2 | monomer | 100.0 | ||||
| CDK2 in complex with inhibitor KVR-1-127 | monomer | 100.0 | 1×EDO; 1×X73; | |||
| Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor | monomer | 100.0 | 1×DT1; | |||
| Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor | monomer | 100.0 | 1×2SC; | |||
| CDK2 in complex with inhibitor RC-2-132 | monomer | 100.0 | 1×X44; | |||
| Structure of CDK2 in complex with a benzimidazopyrimidine | monomer | 100.0 | 1×ACT; 1×D6I; | |||
| Modulating the interaction between CDK2 and Cyclin A with a Quinoline-based inhibitor | monomer | 100.0 | 1×2KD; | |||
| Human cyclin dependent kinase 2 (CKD2)complexed with DIN-232305 | monomer | 100 | 1×D05; | |||
| Human cyclin dependent kinase 2 (cdk2) complexed with indenopyraxole DIN-101312 | monomer | 100.0 | 1×D31; | |||
| STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873 | monomer | 100.0 | 1×U73; | |||
| CDK2 in complex with inhibitor RC-1-148 | monomer | 100.0 | 1×X36; | |||
| CDK2 in complex with inhibitor RC-1-136 | monomer | 100.0 | 1×Z63; | |||
| CDK2 in complex with inhibitor RC-3-96 | monomer | 100.0 | 1×EDO; 1×99Z; | |||
| CDK2 in complex with inhibitor RC-2-13 | monomer | 100.0 | 6×EDO; 1×X3A; | |||
| CDK2 in complex with inhibitor KVR-1-150 | monomer | 100.0 | 4×EDO; 1×X62; | |||
| CDK2 in complex with inhibitor L3 | monomer | 100.0 | 1×X03; | |||
| Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519… | monomer | 100.0 | 1×LZE; | |||
| HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 | monomer | 100.0 | 1×NW1; | |||
| Cyclin Dependent Kinase 2 (CDK2) with diaminopyrimidine inhibitor | monomer | 100.0 | 1×LIA; | |||
| CDK2 in complex with inhibitor KVR-1-91 | monomer | 100.0 | 1×EDO; 1×19Z; | |||
| CDK2 in complex with inhibitor L4-12 | monomer | 100.0 | 1×06Z; | |||
| CDK2 in complex with inhibitor KVR-1-102 | monomer | 100.0 | 1×EDO; 1×X75; | |||
| CDK2 in complex with inhibitor RC-2-74 | monomer | 100.0 | 1×09Z; | |||
| CDK2 in complex with inhibitor KVR-1-74 | monomer | 100.0 | 1×EDO; 1×X9I; | |||
| Discovery and Characterisation of 2-Anilino-4-(thiazol-5-yl) pyrimidine Transcriptional CDK Inhibit… | monomer | 100.0 | 1×Y8L; | |||
| CDK2 in complex with inhibitor L4 | monomer | 100.0 | 5×EDO; 1×X02; | |||
| CDK2 in complex with inhibitor L2-2 | monomer | 100.0 | 4×EDO; 1×X0A; 1×PO4; | |||
| Human cyclin dependent kinase 2 (CDK2) complexed with DPH-042562 | monomer | 100.0 | 1×D42; | |||
| Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519… | monomer | 100.0 | 1×LZB; | |||
| CDK2 in complex with inhibitor L2-5 | monomer | 100.0 | 1×EDO; 1×X06; 1×PO4; | |||
| CDK2 in complex with inhibitor RC-2-143 | monomer | 100.0 | 1×Z71; | |||
| Crystal structure of the cdk2 in complex with oxindole inhibitor | monomer | 100.0 | 1×45K; 1×GOL; | |||
| Structure of CDK2 in complex with an imidazolyl pyrimidine, compound 5b | monomer | 100.0 | 1×FRT; | |||
| CDK2 in complex with inhibitor KVR-1-67 | monomer | 100.0 | 1×EDO; 1×X88; | |||
| CDK2 in complex with inhibitor KVR-2-88 | monomer | 100.0 | 1×EDO; 1×Z04; | |||
| CDK2 in complex with inhibitor JWS-6-260 | monomer | 100.0 | 1×EDO; 1×X01; | |||
| Crystal structure of CDK2 in complex with 2,4,6-trioxo-1-phenyl- hexahydropyrimidine-5-carboxamide … | monomer | 100.0 | 1×RJI; | |||
| Crystal structure of a benzthiophene inhibitor bound to human Cyclin-dependent Kinase-2 (CDK-2) | monomer | 100.0 | 1×B98; | |||
| CDK2 in complex with inhibitor RC-2-12 | monomer | 100.0 | 1×X46; | |||
| Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519… | monomer | 100.0 | 1×LZC; | |||
| CDK2 in complex with inhibitor RC-2-23 | monomer | 100.0 | 1×02Z; | |||
| Discovery and Characterisation of 2-Anilino-4-(thiazol-5-yl) pyrimidine Transcriptional CDK Inhibit… | monomer | 100.0 | 1×CDK; | |||
| CDK2 in complex with 3 molecules of 8-anilino-1-naphthalene sulfonate | monomer | 100.0 | 1×EDO; 3×2AN; | |||
| Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519… | monomer | 100.0 | 1×LZA; | |||
| CDK2 in complex with inhibitor RC-2-40 | monomer | 100.0 | 1×27Z; | |||
| Human cyclin dependent protein kinase 2 in complex with the inhibitor 2-Amino-6-[(R)-pyrrolidino-5'… | monomer | 100.0 | 1×UN4; | |||
| Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519)… | monomer | 100.0 | 1×GOL; 1×LZ2; | |||
| CDK2 in complex with an imidazole piperazine | monomer | 100.0 | 1×IM9; | |||
| CDK-2 with indazole inhibitor 17 bound at its active site | monomer | 100.0 | 2×EZR; | |||
| CDK2 in complex with inhibitor RC-1-135 | monomer | 100.0 | 1×Z62; | |||
| CDK2 in complex with inhibitor L3-4 | monomer | 100.0 | 1×Z30; | |||
| Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor | monomer | 100.0 | 1×DT2; | |||
| HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE | monomer | 100.0 | 1×BRY; | |||
| HUMAN CYCLIN-DEPENDENT KINASE 2 | monomer | 100.0 | 1×MG; 1×ATP; | |||
| CDK2 in complex with inhibitor YL1-038-31 | monomer | 100.0 | 1×0BX; 1×PO4; | |||
| CDK2 in complex with inhibitor KVR-1-78 | monomer | 100.0 | 2×EDO; 1×X4B; | |||
| CDK2 in complex with inhibitor RC-2-38 | monomer | 100.0 | 4×EDO; 1×X40; | |||
| APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 | monomer | 100.0 | ||||
| CDK2 in complex with inhibitor RC-3-86 | monomer | 100.0 | 1×21Z; | |||
| CDK2 in complex with inhibitor RC-2-135 | monomer | 100.0 | 1×X6B; | |||
| CDK2 in complex with inhibitor NSK-MC1-12 | monomer | 100.0 | 1×EDO; 1×X19; | |||
| CDK2 in complex with inhibitor RC-2-35 | monomer | 100.0 | 1×X43; | |||
| HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(2,5-Dichloro-thiophen-3-yl)-pyrimid… | monomer | 100.0 | 1×CK1; | |||
| HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 | monomer | 100.0 | 1×CMG; | |||
| CDK2 in complex with inhibitor KVR-1-9 | monomer | 100.0 | 1×EDO; 1×Z02; | |||
| CDK2 in complex with inhibitor KVR-1-124 | monomer | 100.0 | 1×EDO; 1×X69; | |||
| Human CDK2 in complex with olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kina… | monomer | 100.0 | 1×CK9; | |||
| Crystal Structure of CDK2 in complex with pan-CDK Inhibitor | monomer | 100.0 | 1×3I6; | |||
| HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-Amino-4-methyl-thiazol-5-yl)-pyr… | monomer | 100.0 | 1×CK7; | |||
| The structure of cyclin-dependent kinase 2 (CDK2) in complex with 4-[(6-amino-4-pyrimidinyl)amino]b… | monomer | 100.0 | 1×U55; | |||
| Structure of CDK2 in complex with a Pyrazolo[4,3-d]pyrimidine Bioisostere of Roscovitine. | monomer | 100.0 | 1×404; | |||
| STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032 | monomer | 100.0 | 1×U32; | |||
| CDK-2 with indazole inhibitor 9 bound at its active site | monomer | 100.0 | 1×EZV; | |||
| CDK2 in complex with SUNITINIB | monomer | 100.0 | 1×B49; 8×EDO; | |||
| Crystal structure of human CDK2 complexed with a pyrazolo[1,5-a]pyrimidine inhibitor | monomer | 100.0 | 1×CT7; | |||
| CDK2 in complex with NSC 134199 | monomer | 100.0 | 1×0S0; 1×EDO; | |||
| CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[… | monomer | 100.0 | 1×LS2; | |||
| Crystal structure of CDK2 with inhibitor | monomer | 100.0 | 1×PM1; | |||
| HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR | monomer | 98.92 | 1×1PU; | |||
| Human Cyclin Dependent Kinase 2 (CDK2) bound to azabenzimidazole derivative | monomer | 100.0 | 1×1N3; | |||
| CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMIN… | monomer | 100.0 | 1×LS3; | |||
| CDK2 in complex with Cpd14 (5-fluoro-4-(4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl)-… | monomer | 100.0 | 1×N14; | |||
| CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AM… | monomer | 100.0 | 1×LS4; | |||
| CDK2 in complex with inhibitor JWS-6-52 | monomer | 100.0 | 1×X66; | |||
| CDK2 in complex with staurosporine | monomer | 100.0 | 1×STU; 16×EDO; | |||
| CDK2 in complex with inhibitor RC-2-72 | monomer | 100.0 | 1×07Z; | |||
| Crystal structure of CDK2 liganded with compound TW8972 | monomer | 100.0 | 1×8IL; | |||
| Crystal structure of cyclin-dependent kinase 2 (cdk2-wt) complex with (2s)-n-(5-(((5-tert-butyl-1,3… | monomer | 100.0 | 1×1YG; | |||
| CDK2 in complex with inhibitor RC-1-138 | monomer | 100.0 | 1×50Z; | |||
| CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]M… | monomer | 100.0 | 1×LS5; | |||
| CDK2 in complex with inhibitor RC-2-73 | monomer | 100.0 | 1×EDO; 1×12Z; | |||
| Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519… | monomer | 100.0 | 1×LZ3; | |||
| Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519… | monomer | 100.0 | 1×LZ5; | |||
| CDK2 in complex with inhibitor RC-2-36 | monomer | 100.0 | 2×EDO; 1×X42; | |||
| HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE | monomer | 100.0 | 1×STU; | |||
| Apo CDK2 crystallized from Jeffamine | monomer | 100.0 | 1×EDO; | |||
| Crystal structure of CDK2 in complex with pyrazolopyrimidine inhibitor | monomer | 100.0 | 1×ACT; 1×PDY; | |||
| CDK2 in complex with inhibitor RC-1-132 | monomer | 100.0 | 1×Z31; | |||
| Human cyclin dependent kinase 2 (CDK2) complexed with DIN-234325 | monomer | 100.0 | 1×D23; | |||
| Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519… | monomer | 100.0 | 2×GOL; 1×LZ1; | |||
| HUMAN CYCLIN-DEPENDENT KINASE 2 | monomer | 100.0 | 1×MG; 1×ATP; | |||
| CDK2 complex with a 4-alkynyl oxindole inhibitor | monomer | 100.0 | 1×FMD; | |||
| Human cyclin dependent kinase 2 complexed with the CDK4 inhibitor | monomer | 98.97 | 1×1CD; | |||
| Crystal structure of CDK2 with SAR60, an aminoindazole type inhibitor | monomer | 100.0 | 1×A28; | |||
| Crystal structure of BAY 1000394 (Roniciclib) bound to CDK2 | monomer | 100.0 | 1×R0N; | |||
| Crystal structure of (R,S)-S-{4-[(5-Bromo-4-{[(2R,3R)-2-hydroxy-1-methylpropyl]oxy}- pyrimidin-2-yl… | monomer | 100.0 | 1×6AF; | |||
| Structure of CDK2 in complex with an imidazolyl pyrimidine, compound 5c | monomer | 100.0 | 1×FRV; | |||
| CDK2 ternary complex with SU9516 and ANS | monomer | 100 | 1×EDO; 1×SU9; 2×2AN; | |||
| CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H-PURIN-2- YLAMINE AND MONOMERIC CDK2 | monomer | 100.0 | 1×N69; | |||
| HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B | monomer | 100.0 | 1×PVB; 1×EDO; | |||
| HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 | monomer | 100.0 | 1×MG; 1×ATP; | |||
| Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor | monomer | 100.0 | 1×CT8; | |||
| CDK2 in complex with inhibitor YL5-083 | monomer | 100.0 | 1×0BY; 1×PO4; | |||
| HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE | monomer | 100.0 | 1×HMD; 4×EDO; | |||
| Human cyclin dependent protein kinase 2 in complex with the inhibitor 2-Amino-6-[cyclohex-3-enyl]me… | monomer | 100.0 | 1×207; | |||
| CDK2 in complex with inhibitor RC-2-142 | monomer | 100.0 | 1×Z67; | |||
| Crystal structure of human CDK2 complexed with a pyrazolo[1,5-a]pyrimidine inhibitor | monomer | 100.0 | 1×CT9; | |||
| Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519… | monomer | 100.0 | 1×LZ9; | |||
| Fragment-Based Discovery of the Pyrazol-4-yl urea (AT9283), a Multi- targeted Kinase Inhibitor with… | monomer | 100.0 | 1×L0F; | |||
| CDK2 in complex with the imidazole pyrimidine amide, compound (S)-8b | monomer | 100.0 | 1×ACT; 1×I19; | |||
| Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519… | monomer | 100.0 | 1×LZ8; | |||
| CDK2 complexed with N-methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonam… | monomer | 100.0 | 1×LS1; | |||
| HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR | monomer | 98.9 | 1×2PU; | |||
| Screening for fragment binding by X-ray crystallography | monomer | 100.0 | 1×CIG; | |||
| Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519… | monomer | 100.0 | 1×GOL; 1×LZ4; | |||
| Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519… | monomer | 100.0 | 1×LZ7; | |||
| THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR | monomer | 100.0 | 1×106; | |||
| Crystal structure of human CDK2 in complex with the inhibitor olomoucine. | monomer | 100.0 | 1×OLO; | |||
| Structure of CDK2 with a 3-hydroxychromones | monomer | 100.0 | 1×371; | |||
| THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-6,7-DIMETHOX… | monomer | 100.0 | 1×DTQ; | |||
| Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor | monomer | 100.0 | 1×C53; 1×CL; | |||
| Structure of CDK2 complexed with PNU-181227 | monomer | 100.0 | 1×N5B; | |||
| Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519… | monomer | 100.0 | 1×LZM; | |||
| Crystal structure of CDK2 with SAR57, an aminoindazole type inhibitor | monomer | 100.0 | 1×A27; | |||
| Crystal structure of CDK2 IN complex with Inhibitor NU-6140 | monomer | 100.0 | 1×AQG; | |||
| HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(2,4-Dimethyl-thiazol-5-yl)-pyrim… | monomer | 100.0 | 1×CK8; | |||
| Crystal structure of a 3-aminoindazole compound with CDK2 | monomer | 100.0 | 1×740; | |||
| Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor | monomer | 100.0 | 1×C96; | |||
| Crystal structure of CDK2 with a 2-aminopyrimidine compound | monomer | 100.0 | 1×PMU; | |||
| Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor | monomer | 100.0 | 1×DT4; | |||
| HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidi… | monomer | 100.0 | 1×CK2; | |||
| Imidazopyridines: a potent and selective class of Cyclin-dependent Kinase inhibitors identified thr… | monomer | 100.0 | 1×HDU; | |||
| CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR | monomer | 100.0 | 1×3FP; | |||
| Crystal structure of CDK2 with SAR37, an aminoindazole type inhibitor | monomer | 100.0 | 1×A07; | |||
| Human cyclin-dependent kinase 2 in complex with roscovitine | monomer | 100.0 | 1×RRC; | |||
| CDK2 in complex with staurosporine and 2 molecules of 8-anilino-1-naphthalene sulfonic acid | monomer | 100 | 1×STU; 2×2AN; 4×EDO; | |||
| The structure of cyclin dependent kinase 2 (CKD2) with a trisubstituted naphthostyril inhibitor | monomer | 100.0 | 1×5BN; | |||
| HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-Methyl-2-methylamino-thiazol-5… | monomer | 100.0 | 1×CK6; | |||
| Crystal Structure of CDK2 in complex with Macrocyclic Aminopyrimidine | monomer | 100.0 | 1×PY8; | |||
| HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2,4-Dimethyl-thiazol-5-yl)-pyrimid… | monomer | 100.0 | 1×CK4; | |||
| Crystal Structure of Human Cyclin-Dependent Kinase 2 Complexed with a Nucleoside Inhibitor | monomer | 100 | 1×SU9; | |||
| HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(2,4-Dimethyl-thiazol-5-yl)-pyrim… | monomer | 100.0 | 1×CK5; | |||
| HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-… | monomer | 100.0 | 1×RYU; | |||
| CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717 | monomer | 100.0 | 1×I17; | |||
| HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR | monomer | 100.0 | 1×1PU; | |||
| HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(2,4-Dimethyl-thiazol-5-yl)pyrimi… | monomer | 100.0 | 1×CK3; | |||
| CDK2 in complex with FragLite1 | monomer | 100.0 | 2×BYZ; | |||
| Discovery of (4-Pyrazolyl)-2-Aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependen… | monomer | 100.0 | 1×XKU; | |||
| Ternary complex of CDK2 with small molecule ligands TW8672 and Roscovitine | monomer | 100.0 | 2×EDO; 1×RRC; 1×7TW; | |||
| CDK2 in complex with WEIZ-WX-04-001 | monomer | 100.0 | 1×A1IE9; | |||
| Crystal structure of CDK2 liganded with compound EF3019 | monomer | 100.0 | 3×EDO; 1×8FI; | |||
| CDK2 liganded with ATP and Mg2+ | monomer | 100.0 | 1×EDO; 1×ATP; 1×MG; | |||
| CDK2 in complex with NSC 35676 | monomer | 100.0 | 12×EDO; 1×TIY; | |||
| Crystal structure of CDK2 in complex with 7-hydroxy-4-(morpholinomethyl)chromen-2-one processed wit… | monomer | 100.0 | 1×WY3; | |||
| Crystal structure of CDK2 in complex with 6-chloro-7H-purine processed with the CrystalDirect autom… | monomer | 100.0 | 1×ES4; | |||
| CDK2 in complex with NSC 111848 | monomer | 100.0 | 1×3TI; 8×EDO; | |||
| DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN | monomer | 100.0 | 1×MTW; | |||
| CDK2 in complex with FragLite7 | monomer | 100.0 | 1×DMS; 1×HHQ; | |||
| CDK2 in complex with FragLite31 | monomer | 100.0 | 6×HHT; | |||
| Crystal structure of the cdk2 in complex with aminopyrazole inhibitor | monomer | 100.0 | 1×1CK; 5×NA; | |||
| Crystal structure of apo CDK2 | monomer | 100.0 | ||||
| Crystal structure of CDK2 liganded with compound WN333 | monomer | 100.0 | 1×EDO; 1×80E; | |||
| The structure of cyclin-dependent kinase 2 (CDK2) in complex with Compound 1 | monomer | 100.0 | 1×65L; | |||
| Crystal structure of the cdk2 in complex with oxindole inhibitor | monomer | 100.0 | 1×46K; | |||
| Crystal structure of CDK2 liganded with compound GPHR787 | monomer | 100.0 | 2×7TH; | |||
| Crystal structure of the cdk2 in complex with oxindole inhibitor | monomer | 100.0 | 1×48K; | |||
| Imidazopyridines: a potent and selective class of Cyclin-dependent Kinase inhibitors identified thr… | monomer | 99.63 | 1×HDT; | |||
| Crystal structure of CDK2 in complex with N-(9H-purin-6-yl)thiophene- 2-carboxamide processed with … | monomer | 100.0 | 1×ZXC; | |||
| Ternary complex of CDK2 with small molecule ligands TW8672 and Dinaciclib | monomer | 100.0 | 2×EDO; 1×1QK; 1×7TW; | |||
| Cyclin-free CDK2 in complex with Cpd21 | monomer | 100.0 | 1×GOL; 1×WQK; | |||
| CDK2 IN COMPLEX WITH COMPOUND 4 | monomer | 100.0 | 1×3I3; | |||
| Crystal structure of CDK2 liganded with compound WN378 | monomer | 100.0 | 1×8KF; | |||
| Cdk2(F80C, C177A) with covalent adduct at C80 | monomer | 99.31 | 1×AEQ; | |||
| Crystal structure of CDK2 in complex with inhibitor BS-194 | monomer | 100.0 | 1×NS9; | |||
| CDK2 in complex with a disubstituted 2, 4-bis anilino pyrimidine CDK4 inhibitor | monomer | 100.0 | 2×GOL; 1×FAL; 1×FBL; | |||
| CDK2 in complex with a disubstituted 4, 6-bis anilino pyrimidine CDK4 inhibitor | monomer | 100.0 | 1×MFP; 1×MFQ; | |||
| Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor | monomer | 100.0 | 1×DT5; | |||
| Imidazopyridines: a potent and selective class of Cyclin-dependent Kinase inhibitors identified thr… | monomer | 100.0 | 1×HDY; | |||
| Crystal structure of CDK2 liganded with compound EF2252 | monomer | 100.0 | 1×EDO; 1×88O; | |||
| Crystal structure of CDK2 in complex with inhibitor ICEC0943 | monomer | 100.0 | 1×I73; | |||
| Crystal structure of CDK2 in complex with inhibitor ICEC0942 | monomer | 100.0 | 1×ACT; 1×I74; | |||
| Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor | monomer | 100.0 | 1×CT6; | |||
| Crystal structure of CDK2 liganded with compound WN316 | monomer | 100.0 | 2×EDO; 1×8IQ; | |||
| Human CDK2 with type II inhibitor | monomer | 100.0 | 2×LQ5; | |||
| CDK2 in complex with Luciferin | monomer | 100.0 | 1×ESJ; | |||
| Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor | monomer | 100.0 | 1×4SP; | |||
| Crystal structure of Cdk2 in complex with Cyclin A inhibitor 6-[(E)-2-(4-chlorophenyl)ethenyl]-2-{[… | monomer | 100.0 | 1×OW6; | |||
| Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor | monomer | 100.0 | 1×C62; | |||
| Human cyclin-dependent kinase 2 in complex with inhibitor HB-29260 | monomer | 100.0 | 1×W5W; 1×GOL; | |||
| Cdk2(WT) covalent adduct with D28 at C177 | monomer | 100.0 | 1×9YZ; | |||
| CDK2 with EGFR inhibitor compound 8 | monomer | 100.0 | 1×ACT; 1×3QS; | |||
| Cdk2(WT) with covalent adduct at C177 | monomer | 100.0 | 1×AAK; | |||
| CDK2 liganded with para chloro ANS | monomer | 100.0 | 2×N5R; 1×PO4; 1×EDO; | |||
| Cdk2(F80C, C177A) covalent adduct with C37 at F80C | monomer | 99.28 | 1×9Z2; | |||
| Structure of cyclin-dependent kinase 2 with small-molecule ligand 4- fluorobenzoic acid (AT222) in … | monomer | 100.0 | 2×1Y6; 1×ACE; | |||
| Structure of cyclin-dependent kinase 2 with small-molecule ligand 3-(4,7-dichloro-1H-indol-3-yl)pro… | monomer | 100.0 | 2×MFZ; | |||
| The structure of cyclin dependent kinase 2 (CKD2) with a pyrazolobenzodiazepine inhibitor | monomer | 100.0 | 1×2BZ; | |||
| Aerosol-soaked human cdk2 crystals with Staurosporine | monomer | 100.0 | 1×STU; 2×EDO; | |||
| Cdk2(F80C, C177A) with covalent ligand at F80C | monomer | 99.3 | 1×9ZB; | |||
| CDK2 in complex with a Luciferin derivate | monomer | 100.0 | 2×WG8; | |||
| Crystal structure of CDK2 in complex with 2-imidazol-1-yl-1H- benzimidazole processed with the Crys… | monomer | 100.0 | 1×5JE; | |||
| Structure of CDK2 in complex with FP24322, a Helicon Polypeptide | monomer | 100.0 | 4×EDO; 1×WHL; | |||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 3f5x.2.A | monomer | 0.86 | 1×EZV; | 100.00 | ||
1 SWISS-MODEL model built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 2bpm.1.A | monomer | 0.79 | 1×529; | 89.35 | ||